The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis

Oncogene

Volumn 34, Issue 50, 2015, Pages 6105-6114

  Park, J M ^a   Wu, T ^a   Cyr, A R ^a   Woodfield, G W ^a   De Andrade, J P ^a   Spanheimer, P M ^a   Li, T ^b   Sugg, S L ^a   Lal, G ^a   Domann, F E ^a   Zhang, W ^a   Weigel, R J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN; TCFAP2C PROTEIN; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TCFAP2C PROTEIN, MOUSE; TRANSCRIPTION FACTOR AP 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER TISSUE; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRE GENE; FEMALE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE LOSS; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; TCFAP2C GENE; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; ANIMAL; CARCINOGENESIS; CELL CULTURE; CELL TRANSFORMATION; DISEASE COURSE; GENETICS; MAMMARY NEOPLASMS, EXPERIMENTAL; MOUSE MAMMARY TUMOR VIRUS; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION;

ANIMALS; CARCINOGENESIS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, KNOCKOUT; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSCRIPTION FACTOR AP-2;

EID: 84949591122     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.59     Document Type: Article

References (42)

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
4. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009; 4: e6146.
5. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998; 52: 65-77.
6. Bria E, Carbognin L, Furlanetto J, Pilotto S, Bonomi M, Guarneri V et al. Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: sensitivity analysis of randomized trials. Cancer Treat Rev 2014; 40: 847-856.
7. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
8. Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med 2012; 12: 96-110.
9. Friedrichs N, Steiner S, Buettner R, Knoepfle G. Immunohistochemical expression patterns of AP2alpha and AP2gamma in the developing fetal human breast. Histopathology 2007; 51: 814-823.
10. Zhang J, Brewer S, Huang J, Williams T. Overexpression of transcription factor AP-2alpha suppresses mammary gland growth and morphogenesis. Dev Biol 2003; 256: 127-145.
11. Jager R, Werling U, Rimpf S, Jacob A, Schorle H. Transcription factor AP-2gamma stimulates proliferation and apoptosis and impairs differentiation in a transgenic model. Mol Cancer Res 2003; 1: 921-929.
12. Auman HJ, Nottoli T, Lakiza O, Winger Q, Donaldson S, Williams T. Transcription factor AP-2gamma is essential in the extra-embryonic lineages for early postimplantation development. Development 2002; 129: 2733-2747.
13. Jager R, Schafer S, Hau-Liersch M, Schorle H. Loss of transcription factor AP-2gamma/TFAP2C impairs branching morphogenesis of the murine mammary gland. Dev Dyn 2010; 239: 1027-1033.
14. Cyr AR, Kulak MV, Park JM, Bogachek MV, Spanheimer PM, Woodfield GW et al. TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. Oncogene 2014; 34: 436-444.
15. Woodfield GW, Horan AD, Chen Y, Weigel RJ. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res 2007; 67: 8439-8443.
16. Bogachek MV, Chen Y, Kulak MV, Woodfield GW, Cyr AR, Park JM et al. Sumoylation pathway is required to maintain the basal breast cancer subtype. Cancer Cell 2014; 25: 748-761.
17. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 1996; 13: 1701-1707.
18. Delacroix L, Begon D, Chatel G, Jackers P, Winkler R. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells. DNA Cell Biol 2005; 24: 582-594.
19. Ailan H, Xiangwen X, Daolong R, Lu G, Xiaofeng D, Xi Q et al. Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells. BMC Cancer 2009; 9: 279.
20. Allouche A, Nolens G, Tancredi A, Delacroix L, Mardaga J, Fridman V et al. The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Res 2008; 10: R9.
21. Shiu KK, Wetterskog D, Mackay A, Natrajan R, Lambros M, Sims D et al. Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. Oncogene 2014; 33: 619-631.
22. Turner BC, Zhang J, Gumbs AA, Maher MG, Kaplan L, Carter D et al. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res 1998; 58: 5466-5472.
23. Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J et al. Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer 2004; 40: 1485-1495.
24. Jager R, Friedrichs N, Heim I, Buttner R, Schorle H. Dual role of AP-2gamma in ErbB-2-induced mammary tumorigenesis. Breast Cancer Res Treat 2005; 90: 273-280.
25. Huang S, Chen Y, Podsypanina K, Li Y. Comparison of expression profiles of metastatic versus primary mammary tumors in MMTV-Wnt-1 and MMTV-Neu transgenic mice. Neoplasia 2008; 10: 118-124.
26. Mellentin-Michelotti J, John S, Pennie WD, Williams T, Hager GL. The 5' enhancer of the mouse mammary tumor virus long terminal repeat contains a functional AP-2 element. J Biol Chem 1994; 269: 31983-31990.
27. Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 2006; 16: 649-656.
28. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997; 3: 2099-2106.
29. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010; 7: 403-417.
30. Wagner KU, Booth BW, Boulanger CA, Smith GH. Multipotent PI-MECs are the true targets of MMTV-neu tumorigenesis. Oncogene 2013; 32: 1338.
31. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 2009; 23: 2563-2577.
32. Sale S, Lafkas D, Artavanis-Tsakonas S. Notch2 genetic fate mapping reveals two previously unrecognized mammary epithelial lineages. Nat Cell Biol 2013; 15: 451-460.
33. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 2012; 136: 331-345.
34. Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009; 20: 862-867.
35. Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 2007; 25: 4405-4413.
36. DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res 2011; 13: R44.
37. Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C et al. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci USA 2012; 109: 221-226.
38. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652-6659.
39. Wang X, Bolotin D, Chu DH, Polak L, Williams T, Fuchs E. AP-2alpha: a regulator of EGF receptor signaling and proliferation in skin epidermis. J Cell Biol 2006; 172: 409-421.
40. Spanheimer PM, Askeland RW, Kulak MV, Wu T, Weigel RJ. High TFAP2C/low CD44 expression is associated with an increased rate of pathologic complete response following neoadjuvant chemotherapy in breast cancer. J Surg Res 2013; 184: 519-525.
41. Kulak MV, Cyr AR, Woodfield GW, Bogachek M, Spanheimer PM, Li T et al. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer. Oncogene 2013; 32: 4043-4051.
42. Woodfield GW, Chen Y, Bair TB, Domann FE, Weigel RJ. Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells. Genes Chromosomes Cancer 2010; 49: 948-962.